Please login to the form below

Behavioural insights to navigate complex healthcare markets

Blue Latitude Health Head of Insight Martine Leroy reveals how her team uses behavioural insights to help develop strong pharma brands and services, which successfully navigate complex situations.
The European Union alone spends €700bn (£624 bn) annually on chronic disease management. Healthcare systems, which were initially designed for single disease states, are now required to manage polypharmacy and to also coordinate care. This is an unprecedented challenge. Now, policymakers are developing new care ecosystems, increasingly driven by home care and patient self-management.

There are thousands of health interventions on the market designed to improve patient outcomes – most of them digital. Demand is still growing as more patients, carers and healthcare professionals find themselves navigating complex disease states. Luckily, our learning from behavioural science and its applications has progressed significantly during the last decade and there is growing evidence of what works and does not.

In pharma, our data-rich, evidence-based and technology-driven heritage allows us to translate our learning into brand initiatives that ensure we can develop our brands in complex markets and situations.

At Blue Latitude Health, we apply this novel thinking to launch excellence and service design. Here, we outline how this knowledge can help navigate complex markets, helping our clients to improve care and health outcomes, while optimising brand success.

A perfect storm

Today’s healthcare world relies on a perfect storm of scientific understanding of human behaviour, the public salience of complexity of care, and progress in artificial intelligence. Behavioural science teaches us that patients and healthcare professionals alike are fundamentally people.

Behavioural insights, captured in context, give us a detailed understanding of the true dimensions of stakeholders’ behaviours and possible implications on care.

We are all savvy, demanding, and our expectations of treatments and interventions are soaring. We expect support, digital or otherwise, to be user-friendly, fit into our lifestyles and provide ongoing feedback.

Behavioural theory uncovers true customer insights and shapes brand solutions, which are powerful tools in complex situations. For example, let’s consider the 50 million multimorbidity patients in Europe. They pose a multi-dimensional challenge, from maintaining adherence to poly-medication and managing diseases across disease states, to delivering adequate care at population, sub-group, or individual levels.

The EU-funded Horizon 2020 Digital Health Research Programme, ProAct2020 (Advancing Proactive Digital Integrated Care) aims to develop and evaluate a digital integrated care system to support older adults living with multimorbidity (multiple chronic conditions). ProAct uses behavioural insights to frame, inform and guide its work, and the power of artificial intelligence to align big and small data, ensuring the identification of appropriate care interventions. It is a live and topical pilot example of the perfect storm in action.

The BLH approach: unravelling the complexity

Pharma brands can take advantage of the behavioural insights approach to meet needs and expectations of multiple stakeholders. To do this, our Insight and Customer Experience teams use their extensive experience of behavioural change in complex situations and their deep understanding of the the power of insight to help pharma organisations develop strong brand strategies and plans in complex scenarios.

We use the 
COM-B behavioural logic model and empirical evidence from behavioural interventions to uncover the interventions that work and those that don’t.



Download the full article from Blue Latitude Health


6th June 2018

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

What does the future hold for Medical Affairs?
Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health
Great creative is effective creative. And effective creative is affective creative
Our creative approach at Fishawack Health is Affective Creativity. Creative crafted to make deep, motivating connections with our target audience. We tap into psychology and combine that with creative craft and expertise and to deliver powerful, engaging work on a conscious as well as a subconscious level.
Blue Latitude Health